Safety and effectiveness of a microcrystalline tyrosine-associated mite extract immunotherapy for allergic rhinitis
Por:
Sala-Cunill A, Pérez-Formoso JL, Torán-Barona C, Almeida-Sánchez ZM, Álvarez-Fernández JA, García-Núñez I, Linana-Santafé JJ, Martínez-Tadeo JA, Boronat-Barado A and Justicia JL
Publicada:
1 sep 2020
Ahead of Print:
1 ago 2020
Resumen:
Aim:To assess the safety and effectiveness of an allergen immunotherapy (AIT) with a microcrystalline tyrosine-associated mite allergoid in real-world patients with allergic rhinitis (AR).Materials & methods:Retrospective, multicenter study assessing the safety of AIT in patients aged 5 to 65 years with AR, with or without asthma, sensitized to mites. Secondary objective was effectiveness, measured as unscheduled visits to healthcare centers and emergency rooms, rhinitis and asthma evolution, medication use and patients' and physicians' disease perception 12 months before and after treatment.Results:The 306 patients evaluated, with a mean (standard deviation) age of 29.68 (14.66) years, received different treatment compositions and regimens, and 25 (8.2%) experienced nonserious adverse reactions. Unscheduled visits to the specialist and emergency room admissions significantly decreased after immunotherapy (mean [standard deviation] 2.11 [1.95] and 0.3 [0.93] vs 0.66 [1.09] and 0.02 [0.2], before and after treatment, respectively). Rhinitis and asthma classification ('AR and its impact on asthma' and 'Guia Espanola para el Manejo del Asma', respectively) significantly changed (p < 0.0001 for all classifications), showing symptom reduction after AIT. Median (interquartile range)-combined rhinitis and combined asthma medication scores significantly decreased (4.0 [1.33, 7.0] vs 0.25 [0, 10.0]; p < 0.0001 and 6.94 [1.5, 6.0] vs 0.67 [0, 4.67]; p < 0.0001) within 12 months before and after starting AIT, respectively.Conclusion:AIT with microcrystalline tyrosine-associated mite allergoid appears to be safe and effective in treating rhinitis caused by mites.
Filiaciones:
Sala-Cunill A:
Allergy Section, Internal Medicine Department, Hospital Universitari Vall d'Hebrón, 08035 Barcelona, Spain
Pérez-Formoso JL:
Private Practice Dr. José L. Pérez Formoso, 41004 Sevilla, Spain
Allergology & Immunology Unit, Hospital Fátima, 41012 Sevilla, Spain
Torán-Barona C:
Allergy Therapeutics Ibérica, 08970 Sant Joan Despí, Barcelona, Spain
Almeida-Sánchez ZM:
Allergology Department, La Palma General Hospital, 38713 La Palma, Spain
Álvarez-Fernández JA:
Allergy & Asthma Clinic, 33008 Oviedo, Spain
García-Núñez I:
Pneumokal Research Institute, S.L. 29680 Estepona, Málaga, Spain
Allergology & Pneumology Department, Hospital Quirónsalud Campo de Gibraltar, 11379 Palmones, Los Barrios, Cádiz, Spain
:
Lluis Alcanyís Hospital, 46800 Xátiva, Valencia, Spain
Martínez-Tadeo JA:
University Hospital Nuestra Señora de la Candelaria, 38010 Santa Cruz de Tenerife, Spain
Boronat-Barado A:
Allergy Therapeutics Ibérica, 08970 Sant Joan Despí, Barcelona, Spain
Justicia JL:
Allergy Therapeutics Ibérica, 08970 Sant Joan Despí, Barcelona, Spain
|